A phase 2, multicenter, open‐label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma
dc.contributor.author | Kudchadkar, Ragini | en_US |
dc.contributor.author | Ernst, Scott | en_US |
dc.contributor.author | Chmielowski, Bartosz | en_US |
dc.contributor.author | Redman, Bruce G. | en_US |
dc.contributor.author | Steinberg, Joyce | en_US |
dc.contributor.author | Keating, Anne | en_US |
dc.contributor.author | Jie, Fei | en_US |
dc.contributor.author | Chen, Caroline | en_US |
dc.contributor.author | Gonzalez, Rene | en_US |
dc.contributor.author | Weber, Jeffrey | en_US |
dc.date.accessioned | 2015-06-01T18:51:34Z | |
dc.date.available | 2016-06-01T20:54:35Z | en |
dc.date.issued | 2015-05 | en_US |
dc.identifier.citation | Kudchadkar, Ragini; Ernst, Scott; Chmielowski, Bartosz; Redman, Bruce G.; Steinberg, Joyce; Keating, Anne; Jie, Fei; Chen, Caroline; Gonzalez, Rene; Weber, Jeffrey (2015). "A phase 2, multicenter, open‐label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma." Cancer Medicine 4(5): 643-650. | en_US |
dc.identifier.issn | 2045-7634 | en_US |
dc.identifier.issn | 2045-7634 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/111757 | |
dc.description.abstract | Survivin is a microtubule‐associated protein believed to be involved in preserving cell viability and regulating tumor cell mitosis, and it is overexpressed in many primary tumor types, including melanoma. YM155 is a first‐in‐class survivin suppressant. The purpose of this Phase 2 study was to evaluate the 6‐month progression‐free survival (PFS) rate in patients with unresectable Stage III or IV melanoma receiving a combination of YM155 plus docetaxel. The study had two parts: Part 1 established the dose of docetaxel that was tolerable in combination with YM155, and Part 2 evaluated the tolerable docetaxel dose (75 mg/m2) in combination with YM155 (5 mg/m2 per day continuous infusion over 168 h every 3 weeks). The primary endpoint was 6‐month PFS rate. Secondary endpoints were objective response rate (ORR), 1‐year overall survival (OS) rate, time from first response to progression, clinical benefit rate (CBR), and safety. Sixty‐four patients with metastatic melanoma were treated with docetaxel and YM155. Eight patients received an initial docetaxel dose of 100 mg/m2 and 56 patients received 75 mg/m2 of docetaxel. Six‐month PFS rate per Independent Review Committee (IRC) was 34.8% (n = 64; 95% CI, 21.3–48.6%), and per Investigator was 31.3% (n = 64; 95% CI, 19.5–43.9%). The best ORR (complete response [CR] + partial response [PR]) per IRC was 12.5% (8/64). The stable disease (SD) rate was 51.6% (33/64), leading to a CBR (CR + PR + SD) of 64.1% (41/64). Estimated probability of 1‐year survival was 56.3%. YM155 is a novel agent showing modest activity when combined with docetaxel for treating patients with melanoma. YM155 was generally well tolerated, but the predetermined primary efficacy endpoint (i.e., 6‐month PFS rate ≥20%) was not achieved.YM155 is a first‐in‐class agent that suppresses surviving. Though YM155 combined with docetaxel was generally well‐tolerated in this study, it showed limited efficacy in the treatment of metastatic melanoma. | en_US |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | melanoma | en_US |
dc.subject.other | survivin protein | en_US |
dc.subject.other | YM155 | en_US |
dc.subject.other | Docetaxel | en_US |
dc.title | A phase 2, multicenter, open‐label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Hematology and Oncology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/111757/1/cam4363.pdf | |
dc.identifier.doi | 10.1002/cam4.363 | en_US |
dc.identifier.source | Cancer Medicine | en_US |
dc.identifier.citedreference | Aamdal, S., I. Wolff, S. Kaplan, R. Paridaens, J. Kerger, J. Schachter, et al. 1994. Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. Eur. J. Cancer 30A: 1061 – 1064. | en_US |
dc.identifier.citedreference | Middleton, M. R., J. J. Grob, N. Aaronson, G. Fierlbeck, W. Tilgen, S. Seiter, et al. 2000. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol. 18: 158 – 166. | en_US |
dc.identifier.citedreference | Atkins, M. B., M. T. Lotze, J. P. Dutcher, R. I. Fisher, G. Weiss, K. Margolin, et al. 1999. High‐dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17: 2105 – 2116. | en_US |
dc.identifier.citedreference | Yamanaka, K., T. Nakahara, T. Yamauchi, A. Kita, M. Takeuchi, F. Kiyonaga, et al. 2011. Antitumor activity of YM155, a selective small‐molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models. Clin. Cancer Res. 17: 5423 – 5431. | en_US |
dc.identifier.citedreference | Yamamoto, T., and N. Tanigawa. 2001. The role of survivin as a new target of diagnosis and treatment in human cancer. Med. Electron. Microsc. 34: 207 – 212. | en_US |
dc.identifier.citedreference | Gradilone, A., P. Gazzaniga, D. Ribuffo, S. Scarpa, E. Cigna, F. Vasaturo, et al. 2003. Survivin, bcl‐2, bax, and bcl‐X gene expression in sentinel lymph nodes from melanoma patients. J. Clin. Oncol. 21: 306 – 312. | en_US |
dc.identifier.citedreference | Nakahara, T., A. Kita, K. Yamanaka, M. Mori, N. Amino, M. Takeuchi, et al. 2007. YM155, a novel small‐molecule survivin suppressant, induces regression of established human hormone‐refractory prostate tumor xenografts. Cancer Res. 67: 8014 – 8021. | en_US |
dc.identifier.citedreference | Satoh, T., I. Okamoto, M. Miyazaki, R. Morinaga, A. Tsuya, Y. Hasegawa, et al. 2009. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin. Cancer Res. 15: 3872 – 3880. | en_US |
dc.identifier.citedreference | Lewis, K. D., W. Samlowski, J. Ward, J. Catlett, L. Cranmer, J. Kirkwood, et al. 2011. A multi‐center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest. New Drugs 29: 161 – 166. | en_US |
dc.identifier.citedreference | Giaccone, G., P. Zatloukal, J. Roubec, K. Floor, J. Musil, M. Kuta, et al. 2009. Multicenter phase II trial of YM155, a small‐molecule suppressor of survivin, in patients with advanced, refractory, non‐small‐cell lung cancer. J. Clin. Oncol. 27: 4481 – 4486. | en_US |
dc.identifier.citedreference | Cheson, B. D., N. L. Bartlett, J. M. Vose, A. Lopez‐Hernandez, A. L. Seiz, A. T. Keating, et al. 2012. A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B‐cell lymphoma. Cancer 118: 3128 – 3134. | en_US |
dc.identifier.citedreference | Giodini, A., M. J. Kallio, N. R. Wall, G. J. Gorbsky, S. Tognin, P. C. Marchisio, et al. 2002. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res. 62: 2462 – 2467. | en_US |
dc.identifier.citedreference | Mesri, M., M. Morales‐Ruiz, E. J. Ackermann, C. F. Bennett, J. S. Pober, W. C. Sessa, et al. 2001. Suppression of vascular endothelial growth factor‐mediated endothelial cell protection by survivin targeting. Am. J. Pathol. 158: 1757 – 1765. | en_US |
dc.identifier.citedreference | Gogas, H., D. Bafaloukos, and A. Y. Bedikian. 2004. The role of taxanes in the treatment of metastatic melanoma. Melanoma Res. 14: 415 – 420. | en_US |
dc.identifier.citedreference | Bedikian, A. Y., G. R. Weiss, S. S. Legha, H. A. Burris 3rd, J. R. Eckardt, J. Jenkins, et al. 1995. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J. Clin. Oncol. 13: 2895 – 2899. | en_US |
dc.identifier.citedreference | Korn, E. L., P. Y. Liu, S. J. Lee, J. A. Chapman, D. Niedzwiecki, V. J. Suman, et al. 2008. Meta‐analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression‐free and overall survival benchmarks for future phase II trials. J. Clin. Oncol. 26: 527 – 534. | en_US |
dc.identifier.citedreference | Tolcher, A. W., A. Mita, L. D. Lewis, C. R. Garrett, E. Till, A. I. Daud, et al. 2008. Phase I and pharmacokinetic study of YM155, a small‐molecule inhibitor of survivin. J. Clin. Oncol. 26: 5198 – 5203. | en_US |
dc.identifier.citedreference | Grossman, D., J. M. McNiff, F. Li, and D. C. Altieri. 1999. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J. Invest. Dermatol. 113: 1076 – 1081. | en_US |
dc.identifier.citedreference | Menzies, A. M., and G. V. Long. 2014. Dabrafenib and trametinib, alone and in combination for BRAF‐mutant metastatic melanoma. Clin. Cancer Res. 20: 2035 – 2043. | en_US |
dc.identifier.citedreference | Hamid, O., C. Robert, A. Daud, F. S. Hodi, W. J. Hwu, R. Kefford, et al. 2013. Safety and tumor responses with lambrolizumab (anti‐PD‐1) in melanoma. N. Engl. J. Med. 369: 134 – 144. | en_US |
dc.identifier.citedreference | Wolchok, J. D., H. Kluger, M. K. Callahan, M. A. Postow, N. A. Rizvi, A. M. Lesokhin, et al. 2013. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369: 122 – 133. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.